Company Focus
Lundbeck
Latest Lundbeck News
Latest Lundbeck News
Pharmaceutical
Danish CNS specialist Lundbeck today released first-quarter 2025 financials, along with a raised guidance for the full year, sending its shares up more than 9% to 28.80 kroner. 14 May 2025
Pharmaceutical
The European Commission (EC) has approved Danish CNS specialist Lundbeck and Otsuka Pharmaceutical Europe’s Rxulti (brexpiprazole) for the treatment of schizophrenia in adolescents aged 13 years and older. 13 March 2025
Pharmaceutical
Danish CNS specialist Lundbeck today released financial results for fourth-quarter and full-year 2024. 5 February 2025
Biotechnology
Danish CNS specialist Lundbeck announced positive results from the 12-month open-label extension of the Phase Ib/IIa PACIFIC trial, evaluating bexicaserin in participants aged 12-65 with developmental and epileptic encephalopathies (DEEs). 30 January 2025
Pharmaceutical
Full mergers and acquisitions in the pharmaceutical and biotechnology in 2024 fluctuated throughout the year with hardly any in some months and a significant number in other. But one thing was clear – buyers were shying away from big bets on commercially ready medicines in favor of earlier stage drug developers. 3 January 2025
Latest CNS News & Features
Latest CNS News
Insights
Company Spotlight
A Germany-based biotech aiming to grow into a major global biopharmaceutical player by following a company buy-and-build approach.
Latest News & Features of interest to Lundbeck
Pharmaceutical
A major collaboration between the Allen Institute and the Aligning Science Across Parkinson’s (ASAP) initiative is set to transform neurodegenerative disease research by integrating Parkinson’s-specific brain cell data into the Allen Brain Cell (ABC) Atlas. The effort is expected to amplify understanding of the cellular mechanisms driving Parkinson’s and other related conditions, offering scientists a high-resolution view into previously inaccessible datasets. 17 July 2025
Pharmaceutical
Swiss pharma giant Novartis this morning reported second quarter 2025 financial results, showing that net sales were $14.1 billion (+12%, +11% cc), with volume contributing 12 percentage points to growth. This was slightly better than the consensus estimate of $14.02 billion. 17 July 2025
Pharmaceutical
Bayer is giving chief executive Bill Anderson more time to deliver on his ambitious efforts to reshape the German group, extending his contract by three years to March 2029. The move signals strong support from the company’s supervisory board, which voted unanimously in favor of the renewal. 17 July 2025
Pharmaceutical
Shares in US healthcare conglomerate Johnson & Johnson rose by 6% during Wednesday morning’s trading after the presentation of its second-quarter financial results and latest guidance for 2025. 16 July 2025
Biotechnology
Japanese drugmaker JCR Pharmaceuticals has entered into a joint collaboration, option and license agreement with US biotech Acumen Pharmaceuticals to develop a novel therapeutic candidate for the treatment of Alzheimer’s disease (AD), enabled by JCR’s proprietary blood-brain barrier (BBB)-penetrating technology platform, J-Brain Cargo 16 July 2025
Biotechnology
The USA's Institute for Clinical and Economic Review (ICER) has released a Final Evidence Report assessing the comparative clinical effectiveness and value of Sanofi’s tolebrutinib for the treatment of secondary progressive multiple sclerosis (SPMS). 15 July 2025
Biotechnology
Swiss clinical-stage CNS disease specialist Synendos Therapeutics has named Dr George Garibaldi as its chief medical officer (CMO). 15 July 2025
Pharmaceutical
Japan’s largest pharma company Takeda today announced that all primary and secondary endpoints were met in two Phase III randomized, double-blind, placebo-controlled studies of oveporexton (TAK-861). 14 July 2025
Pharmaceutical
South Korean biotech Illimis Therapeutics has raised 58 billion won ($42 million) in a series B round to advance its GAIA platform into the preclinical stage and expand its drug development programs targeting Alzheimer’s disease and immune disorders. 14 July 2025
Biotechnology
Japanese drugmaker Chugai Pharmaceutical has entered into a joint research and license agreement to develop novel therapies for age-related diseases with Singapore-based biotech Gero. 12 July 2025
Latest In Brief for Lundbeck
Pharmaceutical
Ireland-based biopharma Jazz Pharmaceuticals has been called out for a couple of indiscretions by The Prescription Medicines Code of Practice Authority (PMCPA), which was established by the Association of the British Pharmaceutical Industry (ABPI) to operate the ABPI Code of Practice for the Pharmaceutical Industry. 11 July 2025
Latest CNS Ones To Watch News
CNS Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze